SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Gwen Ifill

PatientGwen Ifill
Date of birth1965-09-29
IdentifiersMRN HR-ML032-SYN; SSN (made up) 000-32-5814
Document date2026-01-20
AuthorLorna Achebe-Price, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Endometrial biopsy result and gynecologic oncology consultation. [S]

History of Present Illness

Ms. Ifill returns two weeks after her first visit. The transvaginal ultrasound two days after that visit showed a 16 mm heterogeneous endometrium with internal blood flow and two small fibroids. The endometrial biopsy taken at the first visit, telephoned to her four days later, shows endometrioid adenocarcinoma, FIGO grade 2, with loss of MLH1 and PMS2 staining and a wild-type p53 pattern. CT of the chest, abdomen and pelvis the next week showed an enlarged right external iliac lymph node and an enlarged left para-aortic node, with no disease in the liver, lungs, bones or peritoneum. Dr. Delacroix of gynecologic oncology saw her this morning. The bleeding has lessened to occasional spotting. She has no pain, bowel or bladder change, leg swelling or weight loss. She says she is shaken but glad the answer came quickly, and wants to keep working through treatment if she can. She has had no thoughts of self-harm. [S]

ElementDetail
BiopsyEndometrioid adenocarcinoma, FIGO grade 2; MLH1 and PMS2 lost; p53 wild-type
ImagingUltrasound: endometrium 16 mm, heterogeneous. CT: enlarged right external iliac and left para-aortic nodes; no distant disease
SymptomsSpotting only; no pain
CoordinationGynecologic oncology seen today; surgery in two weeks
Her questionsWhether the nodes mean the cancer has spread, whether it is inherited, and whether she can keep working

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever, night sweats or weight loss
GenitourinaryPositiveOccasional spotting; no urinary symptoms
GastrointestinalNegativeNo abdominal pain or change in bowel habit
RespiratoryNegativeNo cough or breathlessness
CardiovascularNegativeNo leg swelling or calf pain
PsychiatricPositiveWorried and sleeping less; PHQ-9 6 and GAD-7 7; no thoughts of self-harm

6 systems reviewed. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-01-20Body height165cmS
2026-01-20Body weight74.2kgS
2026-01-20Body mass index (BMI) [Ratio]27.3kg/m2S
2026-01-20Systolic blood pressure132mm[Hg]S
2026-01-20Diastolic blood pressure82mm[Hg]S
2026-01-20Heart rate84/minS
2026-01-20Respiratory rate16/minS
2026-01-20Body temperature36.6CelS
2026-01-20Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-01-20Hemoglobin [Mass/volume] in Blood12.1g/dL12-15.5 g/dLNormalS
2026-01-20Leukocytes [#/volume] in Blood by Automated count610*3/uL4-11 10*3/uLNormalS
2026-01-20Neutrophils [#/volume] in Blood by Automated count3.610*3/uL1.5-7.7 10*3/uLNormalS
2026-01-20Platelets [#/volume] in Blood by Automated count27410*3/uL150-400 10*3/uLNormalS
2026-01-20Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-01-20Potassium [Moles/volume] in Serum or Plasma4.3mmol/L3.5-5.1 mmol/LNormalS
2026-01-20Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.59-1.04 mg/dLNormalS
2026-01-20Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M84mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-01-20Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma19U/L7-35 U/LNormalS
2026-01-20Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma21U/L8-35 U/LNormalS
2026-01-20Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.1-1.2 mg/dLNormalS
2026-01-20Albumin [Mass/volume] in Serum or Plasma4.1g/dL3.5-5 g/dLNormalS
2026-01-20Cancer Ag 125 [Units/volume] in Serum or Plasma28U/mL<=35 U/mLNormalS
2026-01-20Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
2026-01-20Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]7{score}S

Physical Exam

Vital signs recorded on 2026-01-20; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 74.2 kg; blood pressure 132/82, pulse 84
AbdomenSoft, non-tender; no mass or fluid
PelvicExamined with Dr. Delacroix and a chaperone: small amount of blood at the cervical os; cervix normal; uterus mobile, slightly enlarged; no adnexal mass or parametrial thickening
Lymph nodesNo inguinal or supraclavicular nodes
ExtremitiesNo leg swelling
PsychiatricComposed, direct and focused; anxious when talking about the nodes

Problems

ProblemClinical statusVerificationCodeProvenance
Postmenopausal bleeding for three weeks, about eight years after her last period, in a woman of 60 who takes no hormone therapy: endometrial cancer must be excluded. Office endometrial biopsy taken today, transvaginal ultrasound this week, and gynecologic oncology review bookedresolvedconfirmed N95.0S — Synthetic presenting problem; no symptom of her real illness was made public. Superseded by the diagnosis at the gynecologic oncology consultation.
Endometrioid adenocarcinoma of the endometrium, FIGO grade 2, mismatch repair deficient (loss of MLH1 and PMS2 staining), p53 wild-type pattern, on office endometrial biopsy, with enlarged right pelvic and para-aortic lymph nodes on CT; surgical staging planned; synthetic modern detail linked to her publicly reported endometrial canceractiveconfirmed C54.1S — Synthetic histology, molecular result and extent; her family gave endometrial cancer as the cause of death (D), and nothing more about it was made public.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationEvaluation of any postmenopausal bleedingAt the first reportUp to dateExamined and sampled at the first visit, without a waiting period
LaboratoryEndometrial tissue samplingAt the first evaluation of postmenopausal bleeding, with transvaginal ultrasoundUp to dateOffice biopsy at the first visit: endometrioid adenocarcinoma, FIGO grade 2
ImagingTransvaginal ultrasoundAt the first evaluation, together with samplingUp to dateEndometrium 16 mm, heterogeneous, with blood flow; two small intramural fibroids
ImagingCT of the chest, abdomen and pelvisBefore primary treatment when high-grade or extrauterine disease is suspectedUp to dateEnlarged right external iliac and left para-aortic nodes; no distant disease
LaboratoryMismatch repair immunohistochemistry (universal Lynch syndrome tumor screen)At diagnosis, on every endometrial cancerUp to dateLoss of MLH1 and PMS2; MSH2 and MSH6 retained
LaboratoryMLH1 promoter methylationReflex when MLH1 is lostOrderedSent on the biopsy today
Laboratoryp53 immunohistochemistry and POLE sequencing (molecular classification)At diagnosis or on the surgical specimenOrderedp53 wild-type pattern on the biopsy; POLE to be sequenced on the surgical specimen
LaboratoryCA-125At diagnosis; afterwards only if raised at diagnosisCompleted today28 U/mL, normal; not to be repeated routinely
LaboratoryBlood count, chemistry and liver tests before surgeryWithin 30 days before surgeryCompleted todayHemoglobin 12.1 g/dL, white cells 6.0, neutrophils 3.6, platelets 274; sodium 139, potassium 4.3, creatinine 0.80 mg/dL, eGFR 84; ALT 19, AST 21, bilirubin 0.5, albumin 4.1
LaboratoryHepatitis B, hepatitis C and HIV screeningBefore systemic cancer treatmentOrderedHepatitis B surface antigen, core antibody and surface antibody, hepatitis C antibody, and HIV drawn today
ReferralGynecologic oncologyBefore any surgery for endometrial cancerCompleted todaySeen this morning; recommendations in the consultation note
ReferralGenetic counselingAt diagnosis when the tumor screen is abnormalDueAfter the methylation result, at the next visit
SurveyDistress and depression screen (PHQ-9)At diagnosis, each treatment phase, and when symptoms changeCompleted todayPHQ-9 6 and GAD-7 7, mild, with worry about the diagnosis; no thoughts of self-harm
Self-managementInformation, support and privacyAt diagnosis and throughoutCompleted todayPlain explanation with written information; she chose who would be told and asked that notes go only to her clinicians

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms (2026); Updated Guidance Regarding the Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Individuals With Postmenopausal Bleeding. Obstet Gynecol 2026;148(1):e87-e91 (PMID 41990335) (2026); Committee Opinion No. 734: The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding. Obstet Gynecol 2018;131(5):e124-e129 (PMID 29683909) (2018); Berek JS, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet 2023;162(2):383-394 (PMID 37337978) (2023); ACOG Practice Bulletin No. 147: Lynch syndrome. Obstet Gynecol 2014;124(5):1042-1054 (PMID 25437740) (2014); Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol 2020 (2020); Clarke MA, et al. Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype. JAMA Oncol 2022;8(6):895-903 (PMID 35511145) (2022); Doll KM, et al. Assessment of Prediagnostic Experiences of Black Women With Endometrial Cancer in the United States. JAMA Netw Open 2020;3(5):e204954 (PMID 32412636) (2020); CMID: Clinical Monitoring Intelligence Database, endometrial cancer and hypothyroidism monographs (2026); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: Surgery in two weeks with Dr. Delacroix. Primary care review three weeks after surgery with the final pathology, the methylation and POLE results, and genetic counseling. Call for heavy bleeding, fever, or leg swelling. Next scheduled visit 2026-02-24: review three weeks after surgical staging: final pathology and molecular class, genetic counseling, and the first cycle of dostarlimab with carboplatin and paclitaxel. [S]